Rossari Biotech Limited — PPTs, 19-07-2026: Investor Presentation

Rossari Biotech kicked off FY27 with a strong performance, posting consolidated revenue of ₹697.2 Cr, a robust 28.2% YoY jump. Profit after Tax (PAT) edged up 4.5% to ₹35.1 Cr. Key segments like HPPC, TSC, and AHN all delivered impressive YoY growth of 28%, 28%, and 27% respectively, underscoring broad-based momentum.

The company is strategically focused on deepening market penetration, expanding new applications, and boosting its international footprint. Key priorities include optimizing capacity from recent investments and enhancing operational efficiencies.

Recently, Rossari strengthened its Southeast Asia presence by launching a new 5,000 MTPA blending facility in Thailand. It also continued monetizing non-core assets with the sale of its Andheri office.

Q1 FY27 diluted EPS stood at ₹6.3. Management is upbeat, emphasizing a diversified business model and disciplined execution for future profitable growth and long-term value creation.